Impact of one-rod levonorgestrel implant on the blood chemistry profile

Eka R. Gunardi, Raymond Surya, Inayah Syafitri & Yogi Pasidri

The aim of this study was to investigate the effect of a one-rod levonorgestrel implant on the blood chemistry profile, including random blood glucose (RBG), haemoglobin (Hb), alanine transferase (ALT), aspartate transferase (AST), and the lipid profile, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. This prospective cohort study was conducted at Raden Saleh Clinic, Jakarta, from 2010 to 2012. The implants were inserted subdermally in 30 patients. The subjects were evaluated every 6 month up to 2 years. Bivariate analysis using t-test or Wilcoxon signed rank test was performed for all variables. p < 0.05 was considered a significant value. The Hb, RBG, AST, and lipid profile levels were significantly different before and 6 months after one-rod implant insertion (p < 0.05). However, for 24 months, all of the parameters were still within normal limits and did not differ clinically. One-rod levonorgestrel implant insertion has a minimal effect on all blood chemistry profiles.

A long-term contraceptive device that has been widely used is the hormonal implant. The hormonal implant is a contraceptive device that is inserted subdermally in the medial region of the upper arm and contains steroid hormones. There are several kinds of progestogens that may be used in hormonal implants, one of which is levonorgestrel. Levonorgestrel, as a second-generation synthetic progestin and gonane structure derivative, has been widely used as an active compound in hormonal implants. The hormones are slowly released into circulation at the same concentration over a 5-year period. Levonorgestrel levels will rise quickly in the first month after insertion and slowly decrease until the expiration. The hormonal level is also influenced by the subject's body weight. The side effects of synthetic progestin are oedema, abdominal bloating, anxiety, irritability, depression, and myalgia. Monoplant is a hormonal implant that contains 160 mg of levonorgestrel and was developed in Indonesia. Monoplant was estimated to have a contraceptive effect for up to 3 years.

Hormonal contraceptives, especially combined hormonal contraceptives, are known to affect metabolism and induce changes in lipid, lipoprotein, carbohydrate, and haemostatic factor levels. The metabolic impact of progestin contraceptives has not been investigated thoroughly. Subdermal implant contraceptives are a type of contraceptive that releases low-dose progestin continuously, and implant contraceptives are a type of contraceptive that is continuously developing. Recently, a one-rod levonorgestrel (LNG) implant contraceptive (Monoplant) has been developed. The aim of this study was to investigate the effect of a one-rod levonorgestrel implant on the blood chemistry profile, which includes haemoglobin (Hb), random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and the lipid profile including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides.

Methods

This prospective cohort study was conducted at Raden Saleh Clinic, Jakarta, which is a satellite of Dr. Cipto Mangunkusumo Hospital, from 2010 to 2012. This analytical study with a prospective cohort design aims to assess the effect of one-rod levonorgestrel implants on blood chemistry profiles, including Hb, RBG, AST, ALT, and the lipid profile (total cholesterol, HDL, LDL, and triglycerides). This study was a phase two clinical study, in which one-rod levonorgestrel implants were assessed for the first time in patients. This study was evaluated every 6 month up to 24 months.

The minimum sample size was calculated with a chosen type I error rate of 0.05 and power of 80%, resulting in a minimum of 30 individuals in each group. The subjects in this study were women of reproductive age (20–40 years old) who planned to delay or space their pregnancies. The hormonal status, especially related to the
ovulation process, was examined for each participant. The blood chemistry profile in this study was assessed at Dr. Cipto Mangunkusumo Hospital. The technique was guaranteed as an international standard procedure. The blood chemistry profile was assessed before implant insertion. Every subject was then followed, and the blood chemistry profile was examined at the 6th, 12th, 18th, and 24th months.

The inclusion criteria were women aged 20–40 years who engaged in regular sexual activities, did not use any hormonal contraceptives for the last 6 months, provided informed consent for the study, and were able to participate in the routine examination according to the schedule. The exclusion criteria were women who had an abortion in the last two weeks, had not menstruated after delivery, had not menstruated after stopping oral or injection contraceptives, or participated in other studies during the last 6 months. Other exclusion criteria were the presence of any disease that affects the blood chemistry profile (pelvic inflammatory disease since the last delivery, history of ectopic pregnancy, malignancy, abnormal bleeding, abnormal menstrual cycle, amenorrhea, breast abnormalities, thromboembolism, mental illness including depression, headache, or diabetes mellitus). The study was conducted at Raden Saleh Clinic, Jakarta, from 2010 to 2012.

The implants were inserted subdermally during the first to seventh day of menstruation. The subjects were followed for 6 months with monthly observation. During those periods, Hb, RBG, AST, ALT, and lipid profiles were tested.

Every subject had received an explanation about the study and agreed to be participants. Every subject that was included in this study was given and signed the informed consent form. This study was approved by the ethics committee of the Faculty of Medicine, University of Indonesia (number 176/PT02.FK/ETIK/2009). All experiments were performed in accordance with relevant guidelines and regulations.

**Statistical analysis.** Descriptive distributions are shown as frequencies and percentages. Bivariate analysis using t-test or Wilcoxon signed rank test was performed for all variables. A p value < 0.05 was considered significantly.

**Results**

A total of 30 subjects who were included in this second phase of the clinical study did not get pregnant until the end of the study. There were no drop out subjects during the follow up. The baseline characteristics of the subjects are shown in Table 1.

| Variables         | N (%) | Mean ± SD; Median (Min–Max) |
|-------------------|-------|----------------------------|
| Age (year)        | 31.6 ± 5.5 |
| Education         |       |                            |
| Elementary        | 6 (20%) |                            |
| Junior high school| 6 (20%) |                            |
| Senior high school| 16 (53.3%) |                          |
| College graduate  | 2 (6.7%) |                            |
| Parity            | 2 (1–5) |                            |
| History of contraception | |                        |
| Hormonal injection| 18 (60%) |                            |
| Hormonal pill     | 5 (16.7%) |                           |
| Hormonal implant  | 3 (10%)  |                            |
| Intrauterine device| 1 (3.3%) |                           |
| Others            | 1 (3.3%) |                            |
| No history        | 2 (6.7%) |                            |
| Body mass index (kg/m²) | 22.9 ± 4.4 |                      |

**Table 1.** Baseline characteristics of subjects.

The mean Hb, RBG, AST, ALT, and lipid profile (total cholesterol, HDL, LDL and triglyceride) values before and six months after implant insertion were still in the normal range (Table 2). The levels of Hb, RBG, AST, total cholesterol, LDL, and HDL cholesterol were significantly different before and 6 months after one-rod implant insertion (p < 0.05).

The mean Hb level during the study was normal (12–14 g/dL). The mean RBG level remained at a low level, which was below < 160 mg/mL. The liver function parameters including AST and ALT (< 31 mU/mL), during the observation period were normal. Similar results were observed for the lipid profile, including total cholesterol, HDL, LDL, and triglycerides (Table 3).

**Discussion**

This study aimed to assess the effect of one-rod LNG implants on blood chemical indices, such as Hb, RBG, AST, ALT, and the lipid profile. Based on the results, the total cholesterol level was significantly different before and 6 months after one-rod implant insertion. Observations over two years revealed that there was an increasing trend in total cholesterol. However, it was not clinically significant. This result was similar to the study by Affandi, which investigated a six-rod 36 mg LNG implant (Norplant) in a cross-sectional study. However, this result
The HDL cholesterol level in this study decreased significantly. Studies investigating the effect of levonorgestrel on HDL cholesterol levels have shown variable results. Several studies have reported a significant decrease in HDL cholesterol levels. Three studies reported no change during the first 9 months but a slight significant increase at the 12th month. In other studies, they reported a significant increase 6 months after insertion compared with the level in the control IUD group; however, there was a significant decrease observed in the third and fourth years and a similar level at the beginning of the second and fifth years. Dilbaz B et al. stated that etonogestrel implants, a derivate of progestogen, were associated with a decrease in HDL cholesterol. The decrease observed in the third and fourth years and a similar level at the beginning of the second and fifth years. Dilbaz B et al. stated that etonogestrel implants, a derivate of progestogen, were associated with a decrease in HDL cholesterol. The decrease observed 12 months after implant insertion and 6 months after extraction, while there was a significant decrease observed in the third and fourth years and a similar level at the beginning of the second and fifth years. Dilbaz B et al. stated that etonogestrel implants, a derivate of progestogen, were associated with a decrease in HDL cholesterol. However, the decrease in HDL cholesterol was unlikely to be related to increased cardiovascular function because in this study, HDL at 2 years was still in the normal reference range. All the blood chemistry parameters in this study were in the normal range two years after one-rod implant use. This result was not different from similar studies investigating the effect of LNG on the blood chemistry profile, which is usually not constant. Taheri et al. found that cholesterol and triglyceride levels were unchanged, but still in a normal range. a Paired T-test. b Wilcoxon test.

### Table 2. Blood chemistry profile before and after one-rod implant insertion. Bold values indicate when the levels of Hb, RBG, AST, total cholesterol, LDL, and HDL cholesterol were slightly increase or decrease but still in a normal range. a Paired T-test. b Wilcoxon test.

| Blood chemistry | Before (n = 30) | After (n = 30) | Normal range | p   |
|-----------------|---------------|---------------|--------------|-----|
| Hb (g/dL)      | 13.5 ± 1.2    | 12.8 ± 0.8    | 12–14        | 0.005a |
| RBG (mg/mL)    | 78.6 (55–142) | 78.5 ± 17     | <160         | 0.281a |
| AST (mU/mL)    | 22.4 ± 6.5    | 30.5 (10–94)  | <31          | 0.006a |
| ALT (mU/mL)    | 16.5 (9–53)   | 20.5 (7–93)   | <31          | 0.128a |
| Total cholesterol (mg/mL) | 176.6 ± 22.4 | 180 ± 23.2 | 140–250     | 0.460a |
| LDL (mg/mL)    | 105.9 ± 20.6  | 95.8 ± 21     | <155         | 0.023a |
| HDL (mg/mL)    | 47.5 (33–74)  | 61.4 ± 11.4   | >35          | <0.001b |
| Triglycerides (mg/mL) | 110.5 (62–314) | 90.5 (60–326) | <200      | 0.434b |

### Table 3. The blood chemistry profile during 24 months of follow-up.

was different from most studies that investigated the effect of levonorgestrol on the lipid profile. The total cholesterol level usually decreased significantly during levonorgestrol implant use. Apart from that, progestin-only contraceptives method was not robustly associated with metabolic perturbations. Only contraceptive containing estrogen is responsible for broad metabolic effects such as a higher risk of venous thrombosis, thrombotic stroke, and myocardial infarction. The HDL cholesterol level in this study decreased significantly. Studies investigating the effect of levonorgestrol on HDL cholesterol levels have shown variable results. Several studies have reported a significant decrease in HDL cholesterol levels. Three studies reported no change during the first 9 months but a slight significant increase at the 12th month. In other studies, they reported a significant increase 6 months after insertion compared with the level in the control IUD group; however, there was a decrease in the 12th to 24th months, although it was not significant. Finally, a study with a follow-up period of 5 years in Singapore found that the HDL cholesterol level changed variably over time. A significant decrease was observed 12 months after implant insertion and 6 months after extraction, while there was a significant decrease observed in the third and fourth years and a similar level at the beginning of the second and fifth years. Dilbaz B et al. stated that etonogestrel implants, a derivate of progestogen, were associated with a decrease in total cholesterol and HDL cholesterol. However, the decrease in HDL cholesterol was unlikely to be related to increased cardiovascular function because in this study, HDL at 2 years was still in the normal reference range. All the blood chemistry parameters in this study were in the normal range two years after one-rod implant use. This result was not different from similar studies investigating the effect of LNG on the blood chemistry profile, which is usually not constant. Taheri et al. found that cholesterol and triglyceride levels were unchanged, while AST and ALT levels increased slightly. Dorflinger investigated the metabolic effects of several implant contraceptives, including LNG, etonogestrel, nomegestrol acetate, and Nestorone, on liver function, kidney function, glucose, insulin, haemostasis, and blood pressure. The overall metabolic effects were reported to be minimal. Every parameter in the study was still in the normal range for the study population and changes were not clinically significant. In addition, Bender et al. showed changes in fasting glucose and insulin sensitivity among obese individuals using progestin-only contraceptive methods. Therefore, the benefits should be weighed against the risk for this change in metabolic markers.

Based on the results above, we considered that this one-rod LNG implant (Monoplant) was safe for use because it was not associated with clinical differences during a two-year follow-up. The strength of this study is that it was the first to assess the effect of a one-rod LNG implant (Monoplant) on the blood chemical profile with a prospective cohort approach and similar subjects. However, the factors that influence metabolic markers such as diet, lifestyle, and medication were not assessed, which is a limitation of this study. Furthermore, this study...
should measure fasting blood glucose or HbA1c because RBG is highly influenced by several factors. This study was part of a previous phase II clinical trial and can be used as a basis for a phase III clinical trial in the future.

Conclusion

The insertion of a one-rod levonorgestrel implant can provide an optimal effect in preventing pregnancy. In addition, this one-rod levonorgestrel implant showed minimal effect on all blood chemistry profiles after 2 years of follow-up.

Received: 22 June 2021; Accepted: 1 October 2021
Published online: 11 October 2021

References

1. Affandi, B. et al. Five-year experience with Norplant. Contraception 36(4), 417–428 (1987).
2. Diaz, S. et al. Long-term follow-up of women treated with Norplant implants. Contraception 35(6), 551–567 (1987).
3. Sivin, I. et al. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants. Contraception 56(5), 317–321 (1997).
4. Gunardi, E. R. Monoplant® the Indonesian implant: The overview of implant and its development. Ind. J. Obstetr. Gynecol. 35, 2 (2016).
5. Dorfinger, L. I. Metabolic effects of implantable steroid contraceptives for women. Contraception 65(1), 47–62 (2002).
6. Gunardi, E.R., Studi Farmakologi dan Klinik Susuk KB Levonorgestrel Satu Batang. 2011, University on Indonesia.
7. Study of the effects of the implantable contraceptive Norplant on lipid and lipoprotein metabolism. UN Development Programme/UN Population Fund/WHO/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception, 1999. 59(1): p. 31–45.
8. Affandi, B. et al. Serum lipids in Norplant implants users: A cross-sectional study. Contraception 36(4), 429–434 (1987).
9. Singh, K. & Ratnam, S. S. A study on the effects of Norplant implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women. Contraception 56(2), 77–83 (1997).
10. Suherman, S. K., Affandi, B. & Korver, T. The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception 60(5), 281–287 (1999).
11. Singh, K. et al. Evaluation of liver function and lipid metabolism following Norplant implant removal. Adv. Contracept. 9(1), 41–47 (1993).
12. Dilbaz, B. et al. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 81(6), 510–514 (2010).
13. Taberi, M. et al. Effects of a subdermal levonorgestrel contraceptive implant (Norplant) on serum cholesterol, triglycerides, ALT and AST in Iranian women. Contraception 73(1), 56–58 (2006).
14. Bender, N. M. et al. Effects of progestin-only long-acting contraception on metabolic markers in obese women. Contraception 88(3), 418–425 (2013).

Author contributions

EG was the leading researcher for this study, with major contribution for statistical analysis for the study. RS was a major contributor in writing the manuscript, enumerator, and contributor in statistical analysis. IS was contributor in writing the manuscript. YP was contributor and correspondence author that submit the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Y.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021